

17 - References

References

664 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 References

1. Sink KM, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. *J Am Geriatr Soc* 2008; 56:847-853.
2. Ruxton K, et al. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2015; 80:209-220.
3. Sunderland T, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. *Arch Gen Psychiatry* 1987; 44:418-426.
4. Fox C, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. *J Am Geriatr Soc* 2011; 59:1477-1483.
5. Bishara D, et al. The anticholinergic effect on cognition (AEC) scale – associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. *Int J Geriatr Psychiatry* 2020; 35:1069-1077.
6. Bishara D, et al. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. *Int J Geriatr Psychiatry* 2017; 32:650-656.
7. Wagg A. The cognitive burden of anticholinergics in the elderly – implications for the treatment of overactive bladder. *Eur Urol Rev* 2012; 7:42-49.
8. Pagoria D, et al. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. *Curr Urol Rep* 2011; 12:351-357.
9. Womack KB, et al. Tolterodine and memory: dry but forgetful. *Arch Neurol* 2003; 60:771-773.
10. Tsao JW, et al. Transient memory impairment and hallucinations associated with tolterodine use. *N Engl J Med* 2003; 349:2274-2275. Table 6.5 (Continued) Condition Drug class or drug name Drugs to avoid in dementia Recommended drugs in dementia Other GI conditions Antispasmodics Atropine sulphate Dicycloverine hydrochloride Alverine, mebeverine, peppermint oil Hyoscine-n-butylbromide Propantheline bromide Pain Analgesics Pethidine Pentazocine Dextropropoxyphene Codeine Tramadol Methadone Paracetamol Oxycodone Buprenorphine Topical NSAIDs (where appropriate) Fentanyl patches (caution in opioid-naïve patients) Morphine (may be indicated in treatment-resistant pain or palliative care; use cautiously due to associated cognitive and other adverse effects) Urinary frequency Anticholinergic drugs used in overactive bladder Oxybutynin Tolterodine Fesoterodine Darifenacin Trospium Solifenacin (use if others are

not available; some reports of cognitive adverse effects) Data for fesoterodine are still lacking; it is non-selective, has high central anticholinergic activity but theoretically has very low ability to cross the BBB. Urinary retention Alpha blockers Not known to have effects on cognitive function. BBB, blood-brain barrier; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.

Prescribing in older people CHAPTER 6 11. Edwards KR, et al. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. *J Am Geriatr Soc* 2002; 50:1165–1166. 12. Kay G, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. *Eur Urol* 2006; 50:317–326. 13. Lipton RB, et al. Assessment of cognitive function of the elderly population: effects of darifenacin. *J Urol* 2005; 173:493–498. 14. Chancellor MB, et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. *Drugs Aging* 2012; 29:259–273. 15. Park JW. The effect of solifenacin on cognitive function following stroke. *Dement Geriatr Cogn Dis Extra* 2013; 3:143–147. 16. Liabeuf S, et al. Trospium chloride for overactive bladder may induce central nervous system adverse events. *Eur Geriatr Med* 2014; 5:220–224. 17. Isik AT, et al. Trospium and cognition in patients with late onset Alzheimer disease. *J Nutr Health Aging* 2009; 13:672–676. 18. Geller EJ, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. *Female Pelvic Med Reconstr Surg* 2017; 23:118–123. 19. Heesakkers J, et al. Safety and tolerability of fesoterodine in older adult patients with overactive bladder. *Can Geriatr J* 2022; 25:72–78. 20. Wagg A. Fesoterodine fumarate for the treatment of overactive bladder in the elderly – a review of the latest clinical data. *Clin Investig* 2012; 2:825–833. 21. Yonguc T, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease. *World J Urol* 2020; 38:2013–2019. 22. Joint Formulary Committee. British National Formulary (online). London: BMJ and Pharmaceutical Press; <http://www.medicinescomplete.com>. 23. Mahdy AM, et al. Histamine and antihistamines. *Anaesth Intens Care Med* 2011; 12:324–329. 24. Roy-Desruisseaux J, et al. Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. *Ann Pharmacother* 2011; 45:e51. 25. Medicines and Healthcare products Regulatory Agency. Domperidone: risks of cardiac side effects – indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use. 2014; <http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON418518>. 26. Bentley KR, et al. Therapeutic potential of serotonin 5-HT₃ antagonists in neuropsychiatric disorders. *CNS Drugs* 1995; 3:363–392. 27. Gridelli C. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. *Drugs Aging* 2004; 21:825–832. 28. Flicker C, et al. Hypersensitivity to scopolamine in the elderly. *Psychopharmacology (Berl)* 1992; 107:437–441. 29. Ebert U, et al. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. *Eur J Clin Invest* 1998; 28:944–949. 30. Sanofi. Summary of product characteristics. Buscopan 10 mg tablets. 2020 (last updated November 2021); <https://www.medicines.org.uk/emc/medicine/30089>. 31. Gupta P, et al. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. *Drugs Aging* 2008; 25:415–443. 32. Ramsdell JW, et al. Effects of theophylline and ipratropium on cognition in elderly patients with chronic obstructive pulmonary disease. *Ann Allergy Asthma Immunol* 1996; 76:335–340. 33. Fritze J, et al. Pirenzepine for clozapine-induced hypersalivation. *Lancet* 1995; 346:1034. 34. Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008 – present). *Expert Opin Ther Pat* 2012; 22:871–886. 35. Gray SL, et al. Drug-induced cognition disorders in the elderly: incidence, prevention and management. *Drug Saf* 1999;

21:101–122. 36. Bailey RB, et al. Chronic salicylate intoxication. A common cause of morbidity in the elderly. *J Am Geriatr Soc* 1989; 37:556–561. 37. Hoppmann RA, et al. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. *Arch Intern Med* 1991; 151:1309–1313. 38. Wysenbeek AJ, et al. Assessment of cognitive function in elderly patients treated with naproxen. A prospective study. *Clin Exp Rheumatol* 1988; 6:399–400. 39. Bruce-Jones PN, et al. Indomethacin and cognitive function in healthy elderly volunteers. *Br J Clin Pharmacol* 1994; 38:45–51. 40. Barber JB, et al. Treatment of chronic non-malignant pain in the elderly: safety considerations. *Drug Saf* 2009; 32:457–474. 41. Ripamonti C, et al. CNS adverse effects of opioids in cancer patients. *CNS Drugs* 1997; 8:21–37. 42. Alagiakrishnan K, et al. An approach to drug induced delirium in the elderly. *Postgrad Med J* 2004; 80:388–393. 43. McLachlan AJ, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. *Br J Clin Pharmacol* 2011; 71:351–364. 44. Dosa DM, et al. Frequency of long-acting opioid analgesic initiation in opioid-naïve nursing home residents. *J Pain Symptom Manage* 2009; 38:515–521. 45. Tannenbaum C, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. *Drugs Aging* 2012; 29:639–658. 46. McGuinness B, et al. Statins for the treatment of dementia. *Cochrane Database Syst Rev* 2014; 7:CD007514. 47. Wagstaff LR, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy* 2003; 23:871–880. 48. Zhou Z, et al. Effect of statin therapy on cognitive decline and incident dementia in older adults. *J Am Coll Cardiol* 2021; 77:3145–3156. 49. McGuinness B, et al. Statins for the prevention of dementia. *Cochrane Database Syst Rev* 2016; 1:CD003160. 50. Olmastroni E, et al. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. *Eur J Prev Cardiol* 2022; 29:804–814.

666 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 51. Qiu C, et al. The age--dependent relation of blood pressure to cognitive function and dementia. *Lancet Neurol* 2005; 4:487–499. 52. Wändell P, et al. Antihypertensive drugs and relevant cardiovascular pharmacotherapies and the risk of incident dementia in patients with atrial fibrillation. *Int J Cardiol* 2018; 272:149–154. 53. Levi MN, et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. *J Hypertens* 2013; 31:1073–1082. 54. Branco DR, et al. Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-analysis. *J Thromb Thrombolysis* 2023; 56:474–484. 55. Eisendrath SJ, et al. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. *Am J Psychiatry* 1987; 144:506–507. 56. Brezis M, et al. Nightmares from digoxin. *Ann Intern Med* 1980; 93:639–640. 57. Laudisio A, et al. Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey. *Drugs Aging* 2009; 26:103–112. 58. Athwal H, et al. Amiodarone--induced delirium. *Am J Geriatr Psychiatry* 2003; 11:696–697. 59. Foley KT, et al. Separate episodes of delirium associated with levetiracetam and amiodarone treatment in an elderly woman. *Am J Geriatr Pharmacother* 2010; 8:170–174. 60. Cantu TG, et al. Central nervous system reactions to histamine-2 receptor blockers. *Ann Intern Med* 1991; 114:1027–1034. 61. Gomm W, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. *JAMA Neurol* 2016; 73:410–416. 62. Goldstein FC, et al. Proton pump inhibitors and risk of mild cognitive impairment and dementia. *J Am Geriatr Soc* 2017; 65:1969–1974. 63. Lochhead P, et al. Association between proton pump inhibitor use and cognitive function in women. *Gastroenterology* 2017; 153:971–979.e974. 64. Haenisch B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. *Eur Arch Psychiatry Clin Neurosci* 2015; 265:419–428. 65. Cooksey R, et al. Proton pump inhibitors and dementia risk: evidence from a

cohort study using linked routinely collected national health data in Wales, UK. PLoS One 2020; 15:e0237676. 66. Grahl JJ, et al. Antimicrobial exposure and the risk of delirium in critically ill patients. Crit Care 2018; 22:337. 67. Bhattacharyya S, et al. Antibiotic-associated encephalopathy. Neurology 2016; 86:963–971. 68. Kass JS, et al. Nervous system effects of antituberculosis therapy. CNS Drugs 2010; 24:655–667. 69. Bishara D, et al. Safe prescribing of physical health medication in patients with dementia. Int J Geriatr Psychiatry 2014; 29:1230–1241.

Revision #1

Created 2026-01-04 20:16:59 UTC by Omar Ayman

Updated 2026-01-04 20:16:59 UTC by Omar Ayman